Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, texts, and calls has, of course, returned. No matter that this week is leading to a holiday break on this side of the pond; the world keeps spinning. On that note, here is the latest menu of tidbits to get you going. Hope your day goes well and you conquer the world. And as always, do keep in touch. …

Merck (MRK) and several other drug makers are challenging the constitutionality of new Canadian regulations meant to lower patented drug prices in a late bid to derail reforms that would hurt their earnings, Reuters reports. Earlier this month, the Canadian government announced final regulations that give new powers to the Patented Medicine Prices Review Board, and published them in an official register last week, although they do not go effect until July 1.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!